The number of studies concerning bioactive vesicles has significantly increased in recent years with much of this increase stemming from work on exosomes. This class of bioactive vesicles is formed through the fusion of multivesicular bodies (MVBs) with the plasma membrane and release of intraluminal vesicles (ILVs) as exosomes. Originally observed as a mechanism to remove transferrin receptor during reticulocyte maturation [(1)](#b1){ref-type="ref"}, more recent studies have focused on the role of exosomes in antigen presentation (reviewed in [2](#b2){ref-type="ref"}). The presence of antigens on exosomes released from tumor cells and the ability of these exosomes to stimulate anti‐tumor responses *in vitro*and *in vivo*suggest that their use may hold therapeutic promise for cancer patients. An area of very recent interest has been on exosomes role in the spread of pathogens as well as their potential function in promoting or regulating an immune response upon infection. Studies have shown that exosomes may function in the cell‐to‐cell spread of HIV [3](#b3){ref-type="ref"}, [4](#b4){ref-type="ref"}, although this may simply reflect analogous biogenesis/trafficking of exosome and envelope proteins [(5)](#b5){ref-type="ref"}. Exosomes have also been successfully used as vaccines against various pathogens. Finally, studies have suggested that exosomes released from cells infected with intracellular pathogens such as *Mycobacterium tuberculosis*(*M. tb*) contain microbial components and that these exosomes have immune modulatory activity. In this review, we give a general summary of MVBs and exosomes but focus primarily on their diverse functions as well as their potential usefulness as vaccines and disease biomarkers.

MVB: Biogenesis and Functions {#ss2}
=============================

Eukaryotic cells secrete proteins from the biosynthetic pathway by constitutive exocytosis of secretory vesicles or by regulated release of secretory/storage granules upon appropriate stimulation. However, recently, the endocytic network has also been demonstrated to contain an alternative secretory pathway [(6)](#b6){ref-type="ref"}. Pan and Johnstone were the first to describe this pathway in reticulocytes [7](#b7){ref-type="ref"}, [8](#b8){ref-type="ref"}. Subsequent to its discovery in reticulocytes, it has been shown to be present in many cell types including B lymphocytes [(9)](#b9){ref-type="ref"}, dendritic cells (DCs) [(10)](#b10){ref-type="ref"}, platelets [(11)](#b11){ref-type="ref"}, epithelial cells [(12)](#b12){ref-type="ref"} and neurons [(13)](#b13){ref-type="ref"}. The studies in reticulocytes demonstrated that this alternative secretory pathway involves the fusion of MVBs with the plasma membrane and extracellular release of the material present within the ILVs. The MVB is an intermediate but a well‐defined compartment that is formed from endosomes by invagination of the limiting endosomal membrane.

Although it has been almost 30 years since electron microscopy (EM) studies suggested the presence of MVBs in cells, there are still significant gaps in our understanding of MVB biogenesis [(14)](#b14){ref-type="ref"}. The process has to be well co‐ordinated as it dictates the composition and the fate of ILVs. Only recently have certain mechanisms for protein sorting to MVBs been elucidated and include (i) ubiquitination of the target and (ii) preferential aggregation. Using a *Saccharomyces cerevisiae*experimental system, it has been shown that monoubiquitination of endosomal proteins serves as a signal for sorting to MVBs [(15)](#b15){ref-type="ref"}. Some studies have also suggested that oligoubiquitination may also be a sorting signal for trafficking to MVBs, which may increase MVB sorting efficiency [(16)](#b16){ref-type="ref"}. A key player in MVB biogenesis is the hetero‐oligomeric protein complex, endosomal sorting complex required for transport (ESCRT). ESCRT‐I, ‐II and ‐III recognize monoubiquitinated cargoes and promote their inclusion in MVBs [(14)](#b14){ref-type="ref"}. Once completed, the ESCRT complex dissociates from the MVB membrane aided by the adenosine triphosphatase vacuolar protein sorting 4 (Vps4) and is recycled for subsequent cargo [(17)](#b17){ref-type="ref"}. As summarized in [Figure 1](#f1){ref-type="fig"}, hepatocyte growth factor regulated tyrosine kinase substrate (HRS) binds ubiquitinated cargo while simultaneously recruiting the ESCRT family of proteins and mobilizes the cargo for inclusion into MVBs.

![**MVB biogenesis and exosome release.**Monoubiquitination or aggregation provides the signal for trafficking of proteins and lipids to MVBs. The machinery for sorting ubiquitinated proteins involves the multi‐domain Vps27/HRS protein that acts as a bridge between monoubiquitinated transmembrane proteins and clathrin on endosomes [(94)](#b94){ref-type="ref"}. ESCRT is also a key player in MVB biogenesis. ESCRT‐I, ‐II and ‐III recognize monoubiquitinated cargoes and promote their inclusion in MVBs [(95)](#b95){ref-type="ref"}. Once completed, the ESCRT complex dissociates from the MVB membrane. Interestingly, the proteins within the ILVs are enriched for ubiquitin, indicating that not all of the ubiquitin is removed from proteins upon targeting to the MVB. Fusion of the MVB and release of the ILVs as exosomes are regulated and are known to require PLD, calcium and Rab11. PLD, phospholipase D.](TRA-9-871-g001){#f1}

However, some proteins such as the transferrin receptor are present in ILVs but are not ubiquitinated. These proteins, which lack the sorting signal for ubiquitination, are partitioned into the ILVs based on their intrinsic physical properties and preference to segregate into raft‐like microdomains [(18)](#b18){ref-type="ref"}. Molecular aggregation of transferrin receptor in reticulocytes reroutes the receptor from the recycling compartment to the MVB [(19)](#b19){ref-type="ref"}. Studies by Geminard et al. indicate that the transferrin receptor can interact with the ESCRT machinery despite the lack of ubiquitination [(20)](#b20){ref-type="ref"}. Additional studies have demonstrated that protein aggregation induced by antibodies led to the defective sorting of antigens to MVBs [(19)](#b19){ref-type="ref"}. Thus, protein clustering appears to be a major determinant in protein trafficking to the MVB. Recent studies by Theos et al. demonstrated a trafficking of melanosomal protein Pmel17 to MVBs in an ubiquitin‐ and ESCRT‐independent manner [(21)](#b21){ref-type="ref"}. In summary, not all cargoes are recruited to MVBs by the same mechanism, and there are still significant gaps in our understanding of how different cargoes are targeted to ILVs and how the ILV formation occurs.

In contrast to our limited knowledge of MVB biogenesis, their function has been well defined and plays a central role in endocytic trafficking. In most cell types, the MVBs fuse with the lysosomal compartment and thus shuttle MVB cargo for degradation. However, MVBs can also fuse with the plasma membrane and release their ILVs as 'exosomes'[(22)](#b22){ref-type="ref"}.

Exosomes are 30‐ to 100‐nm lipid bilayer vesicles with a density of 1.13 g/mL (for B cell derived) to 1.19 g/mL (for intestinal cell derived). Biophysically, exosomes are equivalent to cytoplasm enclosed in a lipid bilayer with the external domains of transmembrane proteins exposed to the extracellular environment. EM studies have demonstrated the fusion of the limiting membrane of MVB with the plasma membrane as well as release of ILVs in different cell types of hematopoietic origin, such as Epstein--Barr virus (EBV)‐transformed B cells [(9)](#b9){ref-type="ref"}, mastocytes [(23)](#b23){ref-type="ref"}, DCs [10](#b10){ref-type="ref"}, [24](#b24){ref-type="ref"}, platelets [(11)](#b11){ref-type="ref"}, macrophages [(25)](#b25){ref-type="ref"} and cells of non‐hematopoietic origin like neurons and epithelial cells [(13)](#b13){ref-type="ref"}.

Exosome Composition {#ss3}
===================

The lipid and protein content of exosomes has been extensively analyzed by various techniques including Western blotting, fluorescence‐activated cell sorting, immuno‐EM and mass spectrometry. Exosome composition varies depending on the cell type of origin. Nevertheless, exosomes contain a number of common protein components [(26)](#b26){ref-type="ref"}. As shown in [Figure 2](#f2){ref-type="fig"}, the cytosolic proteins present on exosomes include Rabs, which promote exosome docking and the membrane fusion events [(27)](#b27){ref-type="ref"}. The annexins, including annexin I, II, V and VI, may regulate membrane cytoskeleton dynamics and membrane fusion events [(28)](#b28){ref-type="ref"}. Several adhesion molecules such as intercellular adhesion molecule‐1, CD146, CD9, milk‐fat‐globule EGF‐factor VIII (MFG‐E8), CD18, CD11a, CD11b, CD11c, CD166 and LFA‐3/CD58 have also been identified in exosomal preparations [26](#b26){ref-type="ref"}, [27](#b27){ref-type="ref"}. In addition, several proteins involved in apoptosis are present on exosomes including thioredoxin peroxidase II, Alix, 14‐3‐3 and galectin 3. Exosomes also contain heat‐shock proteins Hsp70 and Hsp90, which can facilitate peptide loading onto major histocompatibility complex (MHC)I and MHCII [(29)](#b29){ref-type="ref"}. One of the characteristic features of exosomes is the tetraspanins, which include CD9, CD63, CD81 and CD82. Exosomes also carry some cell‐specific proteins like MHCII and CD86 present only on exosomes isolated from antigen‐presenting cells (APCs) [(30)](#b30){ref-type="ref"} and MFG‐E8/lactadherin present on exosomes from immature DCs [(31)](#b31){ref-type="ref"}. Exosomes are also enriched in proteins that participate in vesicle formation and trafficking like the lyso‐bisphosphatidic acid (LBPA)‐binding protein Alix [(28)](#b28){ref-type="ref"}. Other proteins detected on exosomes are the metabolic enzymes such as peroxidases, pyruvate and lipid kinases and enolase‐1 [(32)](#b32){ref-type="ref"}. Consistent with their endosomal origin, exosomes typically do not contain endoplasmic reticulum, mitochondria or nuclear proteins.

![**Protein composition of exosomes indicating their name, their location (i.e. membrane bound or soluble) and in some cases their function.**GDI, GTP dissociation inhibitor; ICAM1, intercellular adhesion molecule‐1; CAP‐1, adenylyl cyclase‐associated protein; LAMP, lysosomal associated membrane protein‐1; PGRL, PG regulatory‐like protein.](TRA-9-871-g002){#f2}

Similar to proteins, lipids present on exosomes are characteristic of the cell origin, with most of the lipid analytical work being performed on exosomes derived from reticulocytes [(33)](#b33){ref-type="ref"}, mast cells [(34)](#b34){ref-type="ref"}, B lymphocyte cell lines [(35)](#b35){ref-type="ref"} and human DCs [(34)](#b34){ref-type="ref"}. The typical lipid composition of mast cell‐derived exosomes includes lysophosphatidylcholine, sphingomyelin, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, cholesterol and diglyceride [(34)](#b34){ref-type="ref"}. Although most of these lipids are also present on exosomes isolated from other cell types, and the ratios of these lipids vary. For instance, the cholesterol/phospholipid ratio is higher in B‐cell‐derived exosomes compared with exosomes from mast cells and reticulocytes [(36)](#b36){ref-type="ref"}. Phospholipids like LBPA accumulate in MVBs and appear to play a key role in ILV formation [(37)](#b37){ref-type="ref"}. Recent studies by de Gassart et al. have demonstrated the presence of lipid rafts on the exosomes [(18)](#b18){ref-type="ref"}. These low‐density, Triton‐insoluble fractions are enriched in cholesterol and glycosphingolipids and contain different acylated proteins such as glycosyl‐phosphatidylinositol‐anchored proteins and tyrosine kinases of the Src family [(38)](#b38){ref-type="ref"}.

Exosome Function {#ss4}
================

The release of exosomes provides another mechanism of intercellular communication. Exosome function will depend on the cell type from which they were derived and the composition of exosomes in terms of lipids, carbohydrates and proteins. Because exosomes contain a spectrum of surface molecules, they provide a mechanism to engage different cell receptors simultaneously and for exchange of material between cells.

Alternative secretion of proteins by exosomes {#ss5}
---------------------------------------------

Exosome release was initially characterized as a mechanism to eliminate obsolete proteins during reticulocyte maturation and differentiation. Johnstone et al. showed that sheep red blood cells lose their transferrin receptor during *in vivo*and *in vitro*maturation by exosome release [(39)](#b39){ref-type="ref"}. The transferrin receptor is tightly associated with Hsp70 on exosomes, and the heat‐shock protein may play a role in exosome release from reticulocytes. How soluble proteins that lack a signal sequence are released from cells has been the focus of considerable research, and some mechanisms have recently been defined. One method is through association with exosomes, as observed for the translationally controlled tumor protein (TCTP), a cytoplasmic protein that facilitates an inflammatory response by stimulating histamine release. Tumor suppressor activated pathway 6 (TSAP6), a p53‐inducible 5--6 transmembrane protein, has been reported to associate with exosomes as well as with cytoplasmic TCTP, thus facilitating the release of TCTP through exosomes [(40)](#b40){ref-type="ref"}. A more recent study by Yu et al. demonstrated that exosomes function in the release of some p53‐regulated extracellular proteins and that this effect stems from the upregulation of TSAP6 expression by p53 [(41)](#b41){ref-type="ref"}. Another function attributed to exosomes includes the constitutive extracellular release of tumor necrosis factor (TNF) receptor 1 [(42)](#b42){ref-type="ref"}. This established a new mechanism for release of soluble cytokine receptors, which could compete for ligand binding. The cytokine interleukin (IL)‐1β and possibly the chemokine regulated activation normal T cell expressed and secreted (RANTES) may also be secreted by exosomes [(43)](#b43){ref-type="ref"}. Other studies have defined a role for exosomes in ectodomain shedding and consequently a vehicle for the cellular export of soluble molecules like L1 (CD171) and CD44 in ovarian carcinoma cells [(44)](#b44){ref-type="ref"}. A study by Azevedo et al. showed that in sepsis, nitric oxide and bacterial elements are responsible for type‐specific platelet‐derived exosome generation [(45)](#b45){ref-type="ref"}. These exosomes play an active role in vascular signaling as redox active particles, which induced endothelial cell caspase‐3 activation and apoptosis of vascular cells [(46)](#b46){ref-type="ref"}.

Antigen presentation {#ss6}
--------------------

Pioneering studies by Raposo et al. showed that exosomes secreted by EBV‐transformed B cells can stimulate human CD4^+^ T‐cell clones in an antigen‐specific manner [(9)](#b9){ref-type="ref"}. Their studies were the first to document the release of intact MHCII on the exosomes secreted by both human and murine B‐cell lines. Subsequent studies have shown that exosomes produced by mouse DCs pulsed with tumor peptides induced the rejection of established tumors in a T‐cell‐dependent fashion [(10)](#b10){ref-type="ref"}. Exosomes can also transfer antigens from tumor cells to DCs [(47)](#b47){ref-type="ref"} and therefore functions in antigen cross‐presentation. Like DC‐derived exosomes, exosomes from tumor cells carry MHC molecules along with tumor antigens like melan‐A/MART1 (melanoma tumor), which can be recognized by T cells [(27)](#b27){ref-type="ref"}. Together, the data implicate that exosomes can function in presenting tumor antigens to sensitized T cells and can promote tumor rejection *in vivo* [10](#b10){ref-type="ref"}, [43](#b43){ref-type="ref"}. A number of excellent reviews are available on exosomes role in tumor immunity [48](#b48){ref-type="ref"}, [49](#b49){ref-type="ref"}, [50](#b50){ref-type="ref"}. Interestingly, recent studies by Muntasell et al. showed that in a 24‐h period, ∼12% of the surface‐bound peptide--MHCII complex is endocytosed, trafficked to MVBs and released on exosomes, suggesting that exosome discharge may be a common mechanism to seed secondary lymphoid organs with membrane‐bound antigen [(51)](#b51){ref-type="ref"}.

In addition to their role in antigen presentation, exosomes have also been implicated in immune suppression. This was nicely demonstrated by Peche et al. who showed that injecting donor‐haplotype exosomes from bone marrow DCs before transplantation leads to a significantly prolonged heart allograft survival in congenic and fully MHC‐mismatched Lewis rats [(52)](#b52){ref-type="ref"}. Moreover, *in vivo*studies showed a significant decrease in CD4^+^ T cells in the exosome‐treated recipient, suggesting an immunotolerance effect [(52)](#b52){ref-type="ref"}. Exosomes isolated from immature DCs treated with cytokines, such as IL‐4 and IL‐10, when injected into mice reduced the severity of established collagen‐induced arthritis [53](#b53){ref-type="ref"}, [54](#b54){ref-type="ref"}. DCs that were virally transduced to produce Fas ligand (FasL) also produced exosomes with anti‐inflammatory activity [(55)](#b55){ref-type="ref"}. Therefore, the use of exosomes may be a better therapeutic approach compared with DCs for the treatment of autoimmune diseases such as rheumatoid arthritis. 'Tolerosomes' corresponding to exosome‐like structures are produced by intestinal epithelial cells and could induce tolerance to oral antigens [56](#b56){ref-type="ref"}, [57](#b57){ref-type="ref"}, [58](#b58){ref-type="ref"}. Moreover, exosomes from T cells, melanoma cells and ovarian tumor cells have been shown to carry FasL, which could induce T‐cell apoptosis [59](#b59){ref-type="ref"}, [60](#b60){ref-type="ref"}. Tumor‐derived exosomes may also impair DC development and induce myeloid‐suppressive cells [(61)](#b61){ref-type="ref"}.

Shuttle for RNA {#ss7}
---------------

Elegant studies by Valadi et al. showed that exosomes are enriched in messenger RNA and micro RNA. The exosomes derived from a human (HMC‐1) and mouse (MC/9) mast cell lines were found to transport RNA to neighboring mast cells, which was then translated indicating that the transferred RNA was biologically active. The RNA transferred through exosomes (exosomal shuttle RNA) can confer new functions to the cells [(62)](#b62){ref-type="ref"}.

Shuttle for infectious agents {#ss8}
-----------------------------

The cellular process associated with MVB biogenesis and release has been commandeered during evolution by various pathogens, including viruses, to provide an escape mechanism from the host immune response. Indeed, an evolutionary link between retroviruses and exosome biogenesis has been proposed [(63)](#b63){ref-type="ref"}. Studies with retroviruses have revealed the ability of viruses to hijack the intracellular machinery of MVBs for their budding at the cell surface [(64)](#b64){ref-type="ref"}. HIV utilizes MVBs as the major site for accumulation in human macrophages [25](#b25){ref-type="ref"}, [63](#b63){ref-type="ref"}, and the viruses released have markers commonly found on exosomes. However, although the HIV particles and exosome contain similar components, they may have different origins [(5)](#b5){ref-type="ref"}. Interestingly, recent studies in HIV‐1‐infected macrophages have suggested that HIV‐1 is present within internally sequestered CD63‐positive plasma membrane domains but not in endosomes [(65)](#b65){ref-type="ref"}.

New studies have revealed an unexpected role for exosomes in the spread of prions. Prion diseases are fatal neurodegenerative disorders that affect both humans and animals. Raposo and colleagues have demonstrated that prion protein (PrP) in both its normal (PrP^c^) and its scrappie (PRP^sc^) conformation are trafficked to MVBs and released on exosomes [(66)](#b66){ref-type="ref"}.

Pathogen immune surveillance -- a novel function of exosomes {#ss9}
------------------------------------------------------------

Recent work has yielded substantial insight into the immune responses required for controlling an infection and how pathogens circumvent these mechanisms. It is now apparent that innate effector mechanisms are initiated through specific detection of microbial patterns, which facilitate an immune response. These microbial signatures are referred to as pathogen‐associated molecular patterns (PAMPs) and are specifically recognized by the host's pattern recognition receptors [(67)](#b67){ref-type="ref"}. Therefore, PAMPs expressed on the surface or released by the pathogen play an essential role in stimulating immunity. By their nature, intracellular pathogens show a more limited exposure to the immune system compared with extracellular pathogens, and this includes limited exposure of PAMPs. We and others hypothesized that release of exosomes from infected cells may be one mechanism by which this sequestration of PAMPs can be overcome.

The first evidence to support this hypothesis came from a series of insightful experiments by Russell and colleagues where they identified a number of the mycobacteria cell wall components that were trafficked inside the infected cell [(68)](#b68){ref-type="ref"}. EM studies by Beatty et al. identified mycobacterial PAMPs including lipoarabinomannan (LAM) and phosphatidyl‐myo‐inositol mannosides (PIM) in the endocytic compartment of *Mycobacterium bovis*BCG‐infected macrophages [(68)](#b68){ref-type="ref"}. Density gradient electrophoresis analysis of the infected cells also suggested that released mycobacterial lipids coalesce in the late endosomal/lysosomal compartments, including MVBs [(68)](#b68){ref-type="ref"}. Studies directed toward the trafficking of *Mycobacterium avium*glycopeptidolipids (GPL) also indicated a similar release and trafficking of the GPL inside the macrophages [(69)](#b69){ref-type="ref"}. Moreover, these studies indicated that the mycobacterial PAMPs were not confined to the infected cells but were also trafficked to the neighboring bystander cells [68](#b68){ref-type="ref"}, [69](#b69){ref-type="ref"}, [70](#b70){ref-type="ref"}, [71](#b71){ref-type="ref"}. These results raised an important question about the mechanism of mycobacterial component secretion.

Beatty et al. originally determined that vesicles the size of exosomes contain mycobacterial components [(68)](#b68){ref-type="ref"}. Additional studies indicated that the mycobacterial components, including GPL, LAM, PIM, trehalose dimycolate and phenolic glycolipids, were released from mycobacterial‐infected macrophages through exosomes ([Figure 3A](#f3){ref-type="fig"}) [69](#b69){ref-type="ref"}, [71](#b71){ref-type="ref"} and that these exosomes were captured by the bystander uninfected cells. Interestingly, some of these lipids have been shown to induce a proinflammatory response when introduced to uninfected macrophages. For instance, PIM2 coated on microspheres could induce TNF‐α and mycobacteria‐containing phagosome‐1 in interferon‐γ‐primed bone marrow macrophages or thioglycollate‐elicited peritoneal macrophages [(71)](#b71){ref-type="ref"}. Moreover, as indicated above, exosomes can function to modulate immune responses, including immune stimulation and immune suppression. Our recent studies demonstrated that exosomes derived from *Mycobacterium*‐infected cells were capable of inducing a proinflammatory response as indicated by the TNF‐α and RANTES secretion and inducible nitric oxide synthase (iNOS) induction in naïve cells ([Figure 3B](#f3){ref-type="fig"}) [69](#b69){ref-type="ref"}, [72](#b72){ref-type="ref"}. This response was completely dependent on MyD88, an adaptor molecule required for most Toll‐like receptor signaling [(69)](#b69){ref-type="ref"}. The stimulatory activity of exosomes were also replicated *in vivo*where mice injected with exosomes derived from *M. bovis*bacille Calmette--Guérin (BCG) or *M. tb*‐infected cells induced a TNF‐α and IL‐12p40 response as well as neutrophil and alveolar macrophage recruitment into the bronchoalveolar lavage fluid (BALF) [(69)](#b69){ref-type="ref"}. Exosomes have been shown to be released in the biological fluids like urine [(73)](#b73){ref-type="ref"}, amniotic fluid [(74)](#b74){ref-type="ref"}, BALF [(75)](#b75){ref-type="ref"} and plasma [(76)](#b76){ref-type="ref"}. Exosomes isolated from the BALF of the mice infected with *M. bovis*BCG also contained PAMPs and could induce a proinflammatory response in treated macrophages [(72)](#b72){ref-type="ref"}. These results, for the first time, reveal exosomes ability to induce a proinflammatory response both *in vitro*and *in vivo*.

![**Composition and trafficking of exosomes from infected macrophages with a focus on mycobacterial‐infected cells.**A) A list of microbial or infectious components that have been shown to be on exosomes. These include 'infectious' proteins such as prions as well as HIV. Also shown are microbial molecules, which have been released from the pathogen and trafficked to MVBs and present on exosomes. B) General diagram of how mycobacterial PAMPs are released from the mycobacteria within a phagosome and transported to the MVB for release on exosomes. The exosomes containing the PAMPs bind to pattern recognition receptors (PRRs) on surrounding macrophages leading to macrophage activation. LPS, lipopolysaccharide; MCP, mycobacteria‐containing phagosome; FAP, fibronectin attachment protein; iNOS, inducible nitric oxide synthase; MAPK, mitogen activated protein kinase.](TRA-9-871-g003){#f3}

These experiments supported a role for exosomes in the intercellular transport of mycobacterial components; however, which component(s) induced the proinflammatory response in naïve macrophages was not defined. Insight into this question was provided by our recent studies using the *M. tb*H37Rv *lspA*knockout strain, which lacks the 19‐kDa lipoprotein [(77)](#b77){ref-type="ref"}. Previous studies have indicated that the 19‐kDa lipoprotein of *M. tb*interacts with TLR2 and can induce IL‐12p40 production in macrophages [(78)](#b78){ref-type="ref"}. Exosomes isolated from macrophages infected with the *LspA*‐deficient *M. tb*failed to induce TNF‐α secretion or iNOS production in uninfected macrophages, whereas cells treated with exosomes from wild‐type *M. tb*or the *LspA*‐complemented *M. tb*strain induced both TNF‐α secretion and iNOS production ([Figure 4](#f4){ref-type="fig"}). Together, these data indicate that the 19‐KDa lipoprotein is present on exosomes from *M. tb*‐infected macrophages and is responsible, at least in part, for the exosomes proinflammatory activity.

![**Exosomes isolated from macrophages infected with an *LspA*‐deficient H37Rv fail to stimulate macrophage activation.**Exosomes were isolated from infected J774 cells as described [(81)](#b81){ref-type="ref"} and used to treat bone marrow‐derived murine macrophages. After 24 h, supernatants were isolated and analyzed for TNF‐α by enzyme‐linked immunosorbent assay, and cells were harvested and analyzed for iNOS expression by Western blot as described [(81)](#b81){ref-type="ref"}. Total MAPK p38 was used as a loading control. COMP, the *LspA*mutant complemented with the wild‐type (WT) *LspA*gene; MUT, H37Rv mutant that lacks *LspA*and therefore fails to make the 19‐KDa lipoprotein; RC, untreated cells; UI, exosomes from uninfected cells.](TRA-9-871-g004){#f4}

Interestingly, this phenomenon of immune surveillance in the host by exosomes was not unique to the *Mycobacterium*genus as exosomes isolated from *Salmonella typhimurium*‐ or *Toxoplasma gondii*‐infected macrophages also stimulated a proinflammatory response in uninfected cells [(72)](#b72){ref-type="ref"}. The exosomes isolated from *S. typhimurium*‐infected cells contained lipopolysaccharide, a major bacterial PAMP. Although *T. gondii*maintains an intracellular niche in macrophages quite distinct from mycobacteria or *Salmonella*, exosomes released from infected cells also appear to contain *T. gondii*PAMPs [(72)](#b72){ref-type="ref"}. Nevertheless, the true generality of this mechanism for extracellular release of PAMPs from cells infected with intracellular pathogens remains to be determined, as is the effect these exosomes have on the immune response.

Exosomes as vaccine candidates {#ss10}
------------------------------

The use of exosomes has garnered considerable interest as vaccine candidates for tumor immunotherapy [(79)](#b79){ref-type="ref"}. Much of this interest stems from the difficulty associated with DC‐based immunotherapy and how an exosome‐based approach can overcome some of these difficulties. Tumor cell‐derived exosomes containing tumor antigens plus MHC class I molecules can transfer tumor antigens to DCs to induce a CD8+ T‐cell dependent anti‐tumor immune response [(80)](#b80){ref-type="ref"}. Exosomes released from DCs pulsed with tumor antigens were also shown to elicit strong anti‐tumor responses. Data obtained in mice have shown that exosomes obtained from DCs pulsed with tumor peptides could prime specific cytotoxic T lymphocytes (CTLs) *in vivo*and limit or suppress growth of established murine tumors in a T‐cell‐dependent manner [10](#b10){ref-type="ref"}, [81](#b81){ref-type="ref"}. Interestingly, tumor‐derived exosomes may have broader activity than previously believed as one study showed that exosomes isolated from different tumors inhibited not only syngeneic but also allogenic tumor growth, indicating that tumor‐derived exosomes may harbor some common tumor antigens [(47)](#b47){ref-type="ref"}. Together, these studies indicate that exosomes can be isolated from tumor cells or from DCs pulsed with tumor antigens to deliver a target immunogen capable of inducing an effective immune response and that they may represent a new cell‐free vaccine. Some phase I clinical trials have been completed, and although problems with their use remain, the data suggest that exosome‐based therapy is a viable approach [(82)](#b82){ref-type="ref"}.

The successful use of exosomes in cancer immunotherapy has lead to the hypothesis that they could function as vaccine candidates in the context of infectious diseases. Aline et al. demonstrated that exosomes derived from DCs pulsed with *T. gondii*tachyzoite sonicates could induce a protective immune response against *T. gondii*infection. These exosomes primed an antigen‐specific cellular and humoral immune response, which provided a good protection against both acute and chronic toxoplasmosis [(83)](#b83){ref-type="ref"}. Moreover, CBA/J mice vaccinated with exosomes isolated from *T. gondii*antigen‐pulsed DCs exhibited significantly fewer brain cyst [(84)](#b84){ref-type="ref"}. Another application of exosomes in immunotherapy has been implicated in the treatment of pneumococcal infection in mice [(85)](#b85){ref-type="ref"}. Colino and Snapper showed that murine bone marrow‐derived DCs (BMDCs) pulsed *in vitro*with intact diphtheria toxin (DT)‐released exosomes, which upon injection into mice induce immunoglobulin G (IgG)2b and IgG2a responses specific for DT [(86)](#b86){ref-type="ref"}. Exosomes have also been evaluated in the context of *Streptococcus*infections. Invasive strains of *Streptococcus pneumoniae*are leading causes of meningitis and major causes of otitis media and bacteremia in children and pneumonia in the elderly [(87)](#b87){ref-type="ref"}. Vaccine‐mediated protection against *S*. *pneumoniae*infection is based on humoral immunity specific for *S*. *pneumoniae*capsular polysaccharides (Cps) [(88)](#b88){ref-type="ref"}. Similar to the DT exosomes, BMDCs treated with Cps14 released exosomes enriched in Cps14. These purified exosomes could induce a *S*. *pneumoniae*‐protective Cps14‐specific immunoglobulin M and IgG3 response in naive recipients [(85)](#b85){ref-type="ref"}. Exosomes isolated from *M. bovis*BCG‐infected macrophages could stimulate splenic T cells isolated from BCG‐infected mice (J. S. S., unpublished data), but whether these exosomes can function as vaccine candidates awaits further study. Exosomes as a vaccine has also been explored for atypical severe acute respiratory syndrome (SARS) caused by the positive‐stranded RNA virus, SARS‐associated cornavirus (SARS‐CoV). Studies by Kuate et al. showed that exosomes containing spike S protein of SARS‐CoV induced neutralizing antibody titres [(89)](#b89){ref-type="ref"}. This immune response was further accentuated by priming with the SARS‐S exosomal vaccine and then boosting with the currently used adenoviral vector vaccine [(89)](#b89){ref-type="ref"}.

In addition to the potential use of exosomes as vaccines against infectious diseases, exosomes have also proved useful in treatment of autoimmune diseases in animal models. This is illustrated in studies by Kim et al. who showed that administration of exosomes derived from DCs‐expressing recombinant IL‐4 was able to modulate the activity of APC and T cells *in vivo*, partly through a FasL/Fas‐dependent mechanism, resulting in effective treatment against collagen‐induced arthritis through suppression of the delayed‐type hypersensitivity inflammatory response [(90)](#b90){ref-type="ref"}.

Exosomes as biomarkers {#ss11}
----------------------

The proteins associated with renal diseases could be detected on exosomes isolated from urine, indicating a possible use for urine exosomes as biomarkers [(91)](#b91){ref-type="ref"}. For instance, Pisitkun et al. demonstrated the excretion of exosomes containing aquaporin‐2 protein in autosomal dominant and autosomal recessive nephrogenic diabetes insipidus patients [(73)](#b73){ref-type="ref"}. Similar proteomic studies performed on urinary exosomes generated a long list of molecular signatures, illustrating valuable potential for diagnostic, prognostic and pathophysiological discovery [(92)](#b92){ref-type="ref"}. Similar to reno pathologies, exosomes are also an attractive biomarker candidate for cancer diagnosis with most of the focus centered on bladder cancer. The differentially expressed proteins include psoriasin, kertain‐14, galectin‐7, epidermal fatty acid binding protein (E‐FABP), migration inhibitor factor‐related protein (MRP8) and 14 and stratifin, which may be useful markers for the diagnosis of bladder cancer [(91)](#b91){ref-type="ref"}. Exosomes may also be valuable as biomarkers for infectious diseases, mainly in the context of defining treatment success. Unfortunately, to date, this has not been tested. Exosomes may be particularly useful in the context of tuberculosis (TB) as the time required to test a new TB drug treatment protocol is extensive, leading to high drug development cost as well as delays in the introduction of new medication. A major limitation in developing an efficient drug treatment for TB is the lack of available methodology to identify an early infection as well as determine drug treatment efficacy. Currently, a major goal is to identify disease biomarkers in biological fluids that can be measured relatively inexpensively for early diagnosis of disease and treatment success. We hypothesize that exosomes, whose composition may change during the course of an *M. tb*infection and treatment, may be such a biomarker.

Exosome display technology {#ss12}
--------------------------

Exosome display technology is a novel technique of manipulating the molecular composition of the exosomes and tailoring exosomes with new desirable properties. Recently, exosome display was applied for the induction of epitope‐specific antibody response against tumor biomarkers [(93)](#b93){ref-type="ref"}. This technology opens up new possibilities in designing novel therapies and generating new diagnostic tools. Exosome display has been used to prepare recombinant vesicles carrying cytokines as well as tumor antigens that may or may not have been previously found on exosomes [(79)](#b79){ref-type="ref"}. The targeted co‐delivery of antigens with the activators of DCs, B‐, T‐ or natural killer cells may also accentuate the exosomes efficacy as a vaccine.

Concluding Remarks and Future Direction {#ss13}
=======================================

It has become increasingly clear, as new exosome studies are published, that these small bioactive vesicles are important in a number of biological functions. From their original discovery in the removal of unwanted proteins from maturing reticulocytes to their role in immune surveillance, the inventory of functions continues to grow. As cancer phase I clinical trails have shown, our knowledge of exosomes can be applied therapeutically and the use of exosomes in treatment and diagnostics is also likely to grow. Nevertheless, there are still many unanswered questions including (i) how is fusion of a MVB with the plasma membrane and release of exosomes regulated, (ii) under what circumstances do exosomes function *in vivo*, and what are the consequences of their expression and (iii) how can we modify exosome composition to maximize their efficacy as vaccines or therapeutic agents. As our understanding of exosome formation and function continues to expand, answers to these and many other questions should be forthcoming.
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